Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-08-16
2010-10-05
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S050000, C514S051000
Reexamination Certificate
active
07807654
ABSTRACT:
Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies.
REFERENCES:
patent: 4789666 (1988-12-01), Gennari
patent: 4960759 (1990-10-01), De Luca et al.
patent: 5470838 (1995-11-01), von Borstel et al.
patent: 5583117 (1996-12-01), von Borstel et al.
patent: 5691320 (1997-11-01), von Borstel et al.
patent: 5968914 (1999-10-01), von Borstel et al.
patent: 5981601 (1999-11-01), Nagley et al.
patent: 6258795 (2001-07-01), von Borstel et al.
patent: 6316426 (2001-11-01), von Borstel et al.
patent: 6472378 (2002-10-01), von Borstel
patent: 2001/0005719 (2001-06-01), Von Borstel
patent: 2004/0224920 (2004-11-01), Naviaux
patent: 2005/0123922 (2005-06-01), Cattaneo et al.
patent: 0 462 075 (1991-12-01), None
patent: 817877 (1959-08-01), None
patent: 62-12794 (1987-01-01), None
patent: 4-243830 (1992-08-01), None
patent: 7-228535 (1995-08-01), None
patent: 10-505578 (1998-06-01), None
patent: WO 96 /14063 (1996-05-01), None
patent: WO 97/45127 (1997-12-01), None
patent: WO 00/06174 (2000-02-01), None
patent: WO 00/11952 (2000-03-01), None
patent: 00/50043 (2000-08-01), None
Bren “Alzheimer's: Searching for a Cure”, FDA Consumer Magazine, Jul.-Aug. 2003 Issue, Pub No. FDA 04-1318C rev.
Hollander et al. Am J. Psychiatry (1999), vol. 156:2, pp. 317-320.
Morais, R., and Guertin, D.,Can. J. Biochem., vol. 60, p. 290-294, 1982 “On the contribution of the mitochondrial genome to the growth of Chinese hamster embryo cells in culture”.
Morais, R., et al,In Vitro Cellular&Development Biology, vol. 24, No. 7, Jul. 1988, p. 649-658, “Development and Characterization of Continous Avian Cell Lines Depleted of Mitochondrial DNA”.
Bodnar, Andrea G., et al,Biochem. J., (1995) 305:817-822, “Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication”.
Bourgeron, Thomas, et al,The Journal of Biological Chemistry, vol. 268, No. 26; Sep. 15, 1993, pp. 19369-19376, “Fate and expression of the deleted mitochondrial DNA differ between human heteroplasmic skin fibroblast and Epstein-Barr virus-transformed lymphocyte cultures”.
Löffler, Monika, et al,Molecular and Cellular Biochemistry, 174:125-192, 1997, “Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides”.
Page, Theodore, et al,Proc. Natl. Acad. Sci. USA, vol. 94, pp. 11601-11606, Oct. 1997, “Developmental disorder associated with increased cellular nucleotidase activity”.
Secades et al “Methods and Findings in Experimental and Clinical . . . ,” vol. 17, Supp. B, pp. 1-54 (see p. 38, col. 2 through p. 39, col. 1, and 40-43) (1995).
Keilbaugh et al, Mol. Pharm. vol. 44, pp. 702-706 (1993), abstract only.
Dykens et al, J. Neurochem, vol. 63, pp. 584-591, see lines 24-28 of abstract; and p. 589, col. 1, first para. (1994).
Kralovansky et al, Cancer Chemotherapy and Pharmacology, vol. 32, pp. 243-248, see abstract, lines 4-7 (1993).
Lipp et al, Biology of the Neonate, vol. 33, pp. 62-65 , see entire abstract (1978).
Sartori et al, Alcohol, vol. 3, pp. 97-100, see first and last sentences of abstract (Mar. 1986).
Agnati et al, Acta Phys. Scanda., vol. 126, pp. 525-531, see abstract, lines 5-15 (Apr. 1986).
Naviaux et al, “Clinical experience with uridine and triacetyluridine (PN401) therapy of mitochondrial disease,” abstract in meeting program for Mitochondrial Dysfunction in Human Pathology, Sep. 5-7, 1998, Hotel Sofitel, Melbourne, Australia.
U.S. Appl. No. 60/121,588, filed Feb. 23, 1999, Naviaux, Robert K.
Chen et al; “Effect of Anti-Human Immunodeficiency Virus Nucleoside Analogs on Mitochondrial DNA and Its Implication for Delayed Toxicity”; Molec. Pharmacol; 39:625-628; (1991).
Keilbaugh et al; “Anti-Human Immunodeficiency Virus Type 1 Therapy and Peripheral Neuropathy: Prevention of 2′,3′-Dideoxycytidine Toxicity in PC12 Cells, a Neuronal Model, by Uridine and Pyruvate”; Molec. Pharmacol. 44:702-706 (1993).
Current Claims 1-47; Von Borstel; U.S. Appl. No. 09/763,955, filed Feb. 28, 2001.
Current Claims 1-18, 20-42 and 45-46; Von Borstel; U.S. Appl. No. 09/838,136, filed Apr. 20, 2001.
Claims from co-pending U.S. Appl. No. 09/838,136, filed Apr. 20, 2001.
Page, T., et al; “A Syndrome of Megaloblastic Anemia, Immunodeficiency, and Excessive Nucleotide Degradation”;Purine and Pyrimidine Metabolism in Man VII, Part B; pp. 345-348 (1991).
Page, T., et al; “A Syndrome of Seizures and Pervasive Development Disorder Associated with Excessive Cellular Nucleotidase Activity”;Purine and Pyrimidine Metabolism in Man IX; pp. 789-792 (1998).
Ferrante, R.J., et al; “Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease”;The Journal of Neuroscience; 20(12), pp. 4389-4397, Jun. 15, 2000.
Du, Y., et al; “Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease”;PNAS, vol. 98, No. 25; pp. 14469-14674 (Dec. 4, 2001).
Ravina, B.M., et al; “Neuroprotective Agents for Clinical Trials in Parkinson's Disease”;American Academy of Neurology; 60, pp. 1234-1240 (2003).
Saydoff et al. “Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease”,Brain Res. (2003) 994(1):44-54.
Gines et al., “Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice”,Hum Mol Genet. (2003);12(5):497-508 (Abstract).
Lam et al (Eur J Pediatr. Jul. 1997;156(7):562-4. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Lam CW, Lau CH, Williams JC, Chan YW, Wong LJ. Department of Pathology, Princess Margaret Hospital, Lai Chi Kok, Hong Kong).
Krahenbuhl et al (Liver. Jul. 2000;20(4):346-8; Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Krahenbuhl S, Brandner S, Kleinle S, Liechti S, Straumann D. Department of Clinical Pharmacology, University of Berne, Switzerland).
Ritchie et al., “Diagnostic Approach to Polyarticular Joint Pain”,American Family Physician, 68, 6, 1151-1160 (2003).
Page, et al., “A Syndrome of Megaloblastic Anemia, Immunodeficiency, and Excessive Nucleotide Degradation,” in Purine and Pyrimidine Metabolism in Man VII, Part B, Harkness, et al. eds (1991) pp. 345-348.
DiMauro, et al, “Mitochondrial encephalomyopathies: where next?”, Revista de Neurologia (1999) 28(2):164-168.
Luft, “Review: The development of mitochondrial medicine”, Proc. Natl. Acad. Sci. USA (Sep. 1994) 91:8731-8738.
Beal, “Mitochondrial dysfunction in neurodegenerative diseases”, Biochimica et Biophysica Acta (1998) 1366:211-223.
Blass, “Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia”, J. Neurosc. Res. (2001) 66: 851-856.
Bowling, et al., “Minireview: Bioenergetic and Oxidative stress in neurodegenerative diseases”, Life Sciences (1995) 56(14): 1151-1171.
Beal, “Mitochondria, free radicals, and neurodegeneration”, Current Opinion Neurobiol. (1996) 6: 661-666.
Browne, et al, “Oxidative damage and mitochondrial dysfunction in neurodegenerative diseases”, Biochem. Soc. Trans. (1994) 22: 1002-1006.
Schulz, et al., “Mitochondrial dysfunction in movement disorders”, Current Opinion in Neurology (1994) 7:333-339.
Office Action issued by European Patent Office Communication pursuant to Article 96(2) EPC; European Patent Application No. 99 968 207.3-212
Saydoff Joel A.
Von Borstel Reid W.
Lewis Patrick T
Nixon & Vanderhye PC
Wellstat Therapeutics Corporation
LandOfFree
Compositions and methods for treatment of mitochondrial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment of mitochondrial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of mitochondrial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4232246